Skip to main content

Table 5 Defensin genotypes and infection outcomes.

From: Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study

Polymorphism

Genotype

Physician visits‡§

Part 1 p Value*

Part 2 p Value†

Days in bed‡ll

Part 1 p Value*

Part 2 p Value†

DEFA1/DEFA3

       
 

DEFA1 only

0.22 (0.07)

0.23

0.05

0.38 (0.16)

0.60

0.36

 

DEFA1/DEFA3

0.28 (0.02)

  

0.51 (0.06)

  

DEFB1 G-20A

       
 

GG

0.27 (0.04)

0.85

0.88

0.49 (0.10)

0.86

0.98

 

GA

0.26 (0.03)

  

0.48 (0.08)

  
 

AA

0.30 (0.05)

  

0.54 (0.11)

  

DEFB1 C-44G

       
 

CC

0.28 (0.03)

0.81

0.42

0.53 (0.07)

0.93

0.14

 

CG

0.27 (0.04)

  

0.44 (0.10)

  
 

GG

0.18 (0.10)

  

0.28 (0.24)

  

DEFB1 G-52A

       
 

GG

0.29 (0.04)

0.67

0.62

0.47 (0.08)

0.81

0.29

 

GA

0.25 (0.03)

  

0.47 (0.08)

  
 

AA

0.30 (0.06)

  

0.62 (0.14)

  
  1. Definition of abbreviations: DEFA = alpha-defensin; DEFB = beta-defensin.
  2. *Part 1 of the two-part model involves modeling whether an individual has any physician visits or any days in bed due to lower respiratory infection. P values for global haplotype association derived from logistic regression analysis. Decline in lung function status was included as a factor in the analysis.
  3. †Part 2 of the two-part model involves modeling the average number of physician visits or days in bed due to lower respiratory infection given that it is greater than zero. P values for global haplotype association derived from gamma regression analysis. Decline in lung function status was included as a factor in the analysis.
  4. ‡Mean (SE).
  5. §Mean number of visits to a physician for lower respiratory infections per year.
  6. llMean number of days kept in bed for lower respiratory infections per year.